Figure 3.

Association between the frequency of regulatory T cells (Tregs) in peripheral blood mononuclear cells (PBMCs) at baseline and progression-free survival (PFS) after FOLFIRI therapy in patients with colorectal cancer. Patients were categorized based on their frequency of Tregs (< or > 25% of PBMCs) before therapy. A Kaplan–Meier curve is shown for these two groups and the association with PFS. The median PFS for patients with <2.5% Tregs pre-treatment was 23.3 months, and for patients with >2.5% Tregs pre-treatment 10.7 months (p = 0.037, n = 23, 3 patients were censored).